Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 Jun;88(3):405–409. doi: 10.1111/j.1365-2249.1992.tb06462.x

Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.

M F Prummel 1, W M Wiersinga 1, R Van der Gaag 1, M P Mourits 1, L Koornneef 1
PMCID: PMC1554494  PMID: 1606722

Abstract

In various autoimmune diseases circulating levels of soluble IL-2 receptor (sIL-2R) seem to be related to disease activity. Because reliable parameters of disease activity in Graves' ophthalmopathy are lacking, we measured sIL-2R levels in 47 patients with this disorder. The patients had Graves' disease, but no other immune-mediated diseases, had not yet received specific treatment for their ophthalmopathy and were euthyroid during the entire study period. Twenty-one of the 47 patients (45%) had sIL-2R values above the upper normal limit of 650 U/ml, as established in 20 healthy controls. There were no differences between patients with normal (median 469, range 280-644 U/ml) and elevated (median 946, range 678-1588 U/ml) sIL-2R levels regarding duration or severity of the eye disease (as assessed clinically from the total eye score). However, patients with severely enlarged eye muscles had higher sIL-2R values than patients with less severely enlarged eye muscles on CT scan. Patients with elevated sIL-2R tended to have a higher response rate (71%) to a 3-month course of prednisone, than those with normal levels (46%; P = 0.081). Since a successful outcome of prednisone treatment might be representative for disease activity, the elevated sIL-2R levels seem to reflect active inflammation. Although the practical relevance of this finding in individual patients is limited, it underscores the importance of cell-mediated immune responses in this thyroid-related eye disease.

Full text

PDF
405

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bahn R. S., Garrity J. A., Gorman C. A. Clinical review 13: Diagnosis and management of Graves' ophthalmopathy. J Clin Endocrinol Metab. 1990 Sep;71(3):559–563. doi: 10.1210/jcem-71-3-559. [DOI] [PubMed] [Google Scholar]
  2. Balazs C., Farid N. R. Soluble interleukin-2 receptor in sera of patients with Graves' disease. J Autoimmun. 1991 Aug;4(4):681–688. doi: 10.1016/0896-8411(91)90185-f. [DOI] [PubMed] [Google Scholar]
  3. Boumpas D. T., Anastassiou E. D., Older S. A., Tsokos G. C., Nelson D. L., Balow J. E. Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J Clin Invest. 1991 May;87(5):1739–1747. doi: 10.1172/JCI115192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Campen D. H., Horwitz D. A., Quismorio F. P., Jr, Ehresmann G. R., Martin W. J. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 1988 Nov;31(11):1358–1364. doi: 10.1002/art.1780311103. [DOI] [PubMed] [Google Scholar]
  5. Chow C. C., Lai K. N., Leung J. C., Chan J. C., Cockram C. S. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy. Clin Endocrinol (Oxf) 1990 Sep;33(3):317–321. doi: 10.1111/j.1365-2265.1990.tb00496.x. [DOI] [PubMed] [Google Scholar]
  6. Fells P. Management of dysthyroid eye disease. Br J Ophthalmol. 1991 Apr;75(4):245–246. doi: 10.1136/bjo.75.4.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jacobson D. H., Gorman C. A. Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment. Endocr Rev. 1984 Spring;5(2):200–220. doi: 10.1210/edrv-5-2-200. [DOI] [PubMed] [Google Scholar]
  8. Jones I. R. The pathogenesis and treatment of Graves' ophthalmopathy. Postgrad Med J. 1987 Sep;63(743):731–733. doi: 10.1136/pgmj.63.743.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Koukkou E., Panayiotidis P., Alevizou-Terzaki V., Thalassinos N. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism. J Clin Endocrinol Metab. 1991 Oct;73(4):771–776. doi: 10.1210/jcem-73-4-771. [DOI] [PubMed] [Google Scholar]
  10. Lai K. N., Leung J. C., Chow C. C., Cockram C. S. T lymphocyte activation in euthyroid Graves' ophthalmopathy: soluble interleukin 2 receptor release, cellular interleukin 2 receptor expression and interleukin 2 production. Acta Endocrinol (Copenh) 1989 May;120(5):602–609. doi: 10.1530/acta.0.1200602. [DOI] [PubMed] [Google Scholar]
  11. Mourits M. P., Koornneef L., Wiersinga W. M., Prummel M. F., Berghout A., van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989 Aug;73(8):639–644. doi: 10.1136/bjo.73.8.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nelson D. L., Rubin L. A., Kurman C. C., Fritz M. E., Boutin B. An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol. 1986 Mar;6(2):114–120. doi: 10.1007/BF00918743. [DOI] [PubMed] [Google Scholar]
  13. Perros P., Kendall-Taylor P. The pathogenesis of thyroid-associated ophthalmopathy. J Endocrinol. 1989 Sep;122(3):619–624. doi: 10.1677/joe.0.1220619. [DOI] [PubMed] [Google Scholar]
  14. Prummel M. F., Mourits M. P., Berghout A., Krenning E. P., van der Gaag R., Koornneef L., Wiersinga W. M. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989 Nov 16;321(20):1353–1359. doi: 10.1056/NEJM198911163212002. [DOI] [PubMed] [Google Scholar]
  15. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  16. Rubin L. A., Nelson D. L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990 Oct 15;113(8):619–627. doi: 10.7326/0003-4819-113-8-619. [DOI] [PubMed] [Google Scholar]
  17. Rubin L. A., Snow K. M., Kurman C. C., Nelson D. L., Keystone E. C. Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. J Rheumatol. 1990 May;17(5):597–602. [PubMed] [Google Scholar]
  18. Rubin L. A. The soluble interleukin-2 receptor in rheumatic disease. Arthritis Rheum. 1990 Aug;33(8):1145–1148. doi: 10.1002/art.1780330814. [DOI] [PubMed] [Google Scholar]
  19. Semenzato G., Bambara L. M., Biasi D., Frigo A., Vinante F., Zuppini B., Trentin L., Feruglio C., Chilosi M., Pizzolo G. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol. 1988 Nov;8(6):447–452. doi: 10.1007/BF00916949. [DOI] [PubMed] [Google Scholar]
  20. Symons J. A., Wood N. C., Di Giovine F. S., Duff G. W. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol. 1988 Oct 15;141(8):2612–2618. [PubMed] [Google Scholar]
  21. Tokano Y., Murashima A., Takasaki Y., Hashimoto H., Okumura K., Hirose S. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis. 1989 Oct;48(10):803–809. doi: 10.1136/ard.48.10.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Weetman A. P. Thyroid-associated eye disease: pathophysiology. Lancet. 1991 Jul 6;338(8758):25–28. doi: 10.1016/0140-6736(91)90013-f. [DOI] [PubMed] [Google Scholar]
  23. Wiersinga W. M., Smit T., Schuster-Uittenhoeve A. L., van der Gaag R., Koornneef L. Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves' ophthalmopathy. Ophthalmologica. 1988;197(2):75–84. doi: 10.1159/000309924. [DOI] [PubMed] [Google Scholar]
  24. Wilson R., McKillop J. H., Buchanan L. M., Bradley H., Smith W. E., Thomson J. A. The effect of carbimazole therapy on interleukin 2, interleukin 2 receptors and free radicals. Autoimmunity. 1990;8(1):3–7. doi: 10.3109/08916939008998426. [DOI] [PubMed] [Google Scholar]
  25. Wood N. C., Symons J. A., Duff G. W. Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun. 1988 Aug;1(4):353–361. doi: 10.1016/0896-8411(88)90005-4. [DOI] [PubMed] [Google Scholar]
  26. van der Gaag R., Broersma L., Mourits M. P., Koornneef L., Wiersinga W. M., Prummel M. P., Berghout A. Circulating monocyte migration inhibitory factor in serum of Graves' ophthalmopathy patients: a parameter for disease activity? Clin Exp Immunol. 1989 Feb;75(2):275–279. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES